ClinicalTrials.gg
CompletedNCT05751629COHORT-AUpdated Apr 21, 2023Results posted

Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer

A Phase 2 interventional study of Dostarlimab and Bevacizumab in Ovarian Neoplasm, sponsored by Tesaro, Inc.. Completed at 10 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-21.

Sponsored by Tesaro, Inc. (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 3 months after the study started (first participant enrolled Nov 2018, registered Feb 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Ovarian Neoplasms by GlaxoSmithKline — 5 open to participants now, 7 under way, 5 of them phase 3. Ovarian Neoplasms · GlaxoSmithKline.

Enrollment
19th of 30
41 · median 77
Started
2018
with 3 others
Phase 2
15 of 31
1 open now
Registered
26th of 31
by date

Among the 31 studies in Ovarian Neoplasms by GlaxoSmithKline, this one is the 19th largest by enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2018, is one of 15 in phase 2, and was the 26th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

5 of the 31 studies in Ovarian Neoplasms by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Ovarian Neoplasms by GlaxoSmithKline, or all of them as a file.
02

Study summary

The primary objective of this sub study is to evaluate the efficacy of the combination of TSR-042, bevacizumab, and niraparib in participants with advanced, relapsed, high-grade ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 2 prior lines of anticancer therapy, are PARP inhibitor naïve, and have platinum-resistant but not refractory disease.

This study is a sub study of the master protocol - OPAL (NCT03574779).

03

Conditions studied

  • Ovarian Neoplasm

Browse trials for

Keywords

  • Poly-ADP-ribose polymerase (PARP) Inhibitor
  • Ovarian cancer
  • Niraparib
  • Bevacizumab
  • TSR-042
  • Neoadjuvant treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be resistant to the most recent platinum-based therapy, defined for the purpose of this protocol as progression within 6 months from completion of a minimum of 4 cycles of platinum-containing therapy. This should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing disease progression. Participant with primary platinum- disease as defined by those who progressed during or within 4 weeks of completion of first platinum-based chemotherapy are not eligible
  • Participant must not have received any prior therapy for ovarian cancer with a PARP inhibitor
  • Participant has had 1 to 2 prior lines of anticancer therapy for ovarian cancer
  • Participant is able to take oral medications.

Exclusion criteria

Exclusion Criteria:

  • Participant has known to TSR-042, bevacizumab, niraparib, their components, or their
  • Participant has a known history of myelodysplastic syndrome or acute myeloid leukemia
  • Participant has active disease that has required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, , or drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
  • Participant received prior treatment with an anti- programmed death-1 () or anti- programmed death-ligand 1 (PD-L1) agent
  • Participant has received prior treatment with anti-angiogenic therapy with the exception of bevacizumab. (Participant who received prior bevacizumab are eligible only if they did not discontinue bevacizumab due to toxicity, as established by the Investigator.)
  • Participant has bowel obstruction, had bowel obstruction within the past 3 months, or is otherwise judged by the Investigator to be at high risk for bowel obstruction related to the underlying disease. Participant has any history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscesses. Evidence of recto-sigmoid involvement by pelvic examination or significant bowel involvement on computed tomography scan
  • Participant has proteinuria as demonstrated by urine protein:creatinine ratio ≥1.0 at screening or urine dipstick for proteinuria ≥2 (Participant discovered to have ≥2 proteinuria on dipstick at baseline should undergo 24-hour urine collection and must demonstrate \<2g of protein in 24 hours to be eligible.)
  • Participant is at increased bleeding risk due to concurrent conditions (eg, major injuries or surgery within the past 28 days prior to start of study treatment, history of hemorrhagic stroke, , subarachnoid hemorrhage, or hemorrhage within the past 3 months)
  • Participant has a history of recent major thromboembolic event defined as follows:

    1. Pulmonary embolism diagnosed within 3 months of enrollment
    2. Lower extremity deep venous thrombosis diagnosed within 3 months of enrollment (Participant with a history of thromboembolic disease on stable therapeutic anticoagulation for more than 3 months prior to enrollment are eligible for this study.)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Cohort A (Dostarlimab + Bevacizumab + Niraparib)

    Drug: Dostarlimab · Drug: Bevacizumab · Drug: Niraparib

Interventions

  • Dostarlimab was administered.

    Also known as: TSR-042

  • Bevacizumab was administered.

    Also known as: Avastin

  • Niraparib was administered.

    Also known as: ZEJULA

06

What researchers measure

Primary outcomes

  1. Confirmed Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment

    ORR was defined as percentage of participants with a confirmed investigator-assessed Best Overall Response (BOR) of confirmed complete response (CR) or partial response (PR), evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR is defined as the disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm).

    Time frame: Up to approximately 38 Months

Secondary outcomes

  1. Progression Free Survival (PFS) Per RECIST Version 1.1 by Investigator Assessment

    PFS was defined as the time from the date of the first dose of study treatment to the earliest date of assessment of disease progression or death by any cause in the absence of progression by RECIST v1.1. Disease Progression is defined using RECIST v1.1 as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Up to approximately 38 Months

  2. Overall Survival (OS)

    OS was defined as the time from the date of the first dose of study treatment to the date of death due to any cause. Median and 95% CI are presented.

    Time frame: Up to approximately 38 Months

  3. Duration of Response (DOR) Per RECIST Version 1.1 by Investigator Assessment

    DOR was defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 based on Investigator's assessment or death by any cause. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm).

    Time frame: Up to approximately 38 Months

  4. Disease Control Rate (DCR) Per RECIST Version 1.1 by Investigator Assessment

    DCR was defined as the percentage of participants who have achieved best overall response of CR, PR, or stable disease (SD) per RECIST version 1.1 based on Investigator's assessment. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Up to approximately 38 Months

  5. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 38 Months

  6. Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters - Chemistry, Coagulation, Hematology and Thyroid

    Blood samples were collected for the analysis of clinical laboratory parameters - chemistry, coagulation, hematology and thyroid.

    Time frame: Up to approximately 38 Months

  7. Absolute Values in Urinalysis Parameter - Specific Gravity (Ratio)

    Urine samples were collected at indicated time points for the assessment of specific gravity. Baseline is defined as the most recent non-missing measurement prior to or on the first administration of study drug.

    Time frame: Baseline (Day 1) and end of treatment (Up to approximately 32 months)

  8. Change From Baseline in Cancer Antigen 125 (CA-125) at End of Treatment

    Blood samples were collected for the analysis of CA-125. Baseline is defined as the most recent non-missing measurement prior to or on the first administration of study drug.

    Time frame: Baseline (Day 1) and end of treatment (Up to approximately 32 months)

  9. Change From Baseline in Vital Signs (Weight) at End of Treatment

    Weight was measured in ordinary indoor clothing (without shoes) and was recorded at specified study visit. Baseline is defined as the most recent non-missing measurement prior to or on the first administration of study drug.

    Time frame: Baseline (Day 1) and end of treatment (Up to approximately 32 months)

  10. Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status at Baseline and End of Treatment

    Performance status assessments were based on 5-grade ECOG scale (from 0 to 4), where 0=fully active, able to carry on all pre-disease performance without restriction; 1=restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (e.g., light house work, office work); 2=ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours; 3=capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed or chair. Baseline is defined as the most recent non-missing measurement prior to or on the first administration of study drug.

    Time frame: Baseline (Day 1) and end of treatment (Up to approximately 32 months)

07

Results

Posted Apr 21, 2023

Participant flow

Participant flow — Overall Study
MilestoneCohort A (Dostarlimab + Bevacizumab + Niraparib)
Started41
Completed0
Not completed41
Withdrew: Withdrawal by subject6
Withdrew: Death25
Withdrew: Study site closed9
Withdrew: Physician decision1

Outcome measures

PrimaryConfirmed Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment

ORR was defined as percentage of participants with a confirmed investigator-assessed Best Overall Response (BOR) of confirmed complete response (CR) or partial response (PR), evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR is defined as the disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm).

Time frame:
Up to approximately 38 Months
Reported as:
Number · Percentage of participants
Confirmed Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment
Percentage of participantsCohort A (Dostarlimab + Bevacizumab + Niraparib)
Confirmed Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment17.9 (10.3 to 28.3)
SecondaryProgression Free Survival (PFS) Per RECIST Version 1.1 by Investigator Assessment

PFS was defined as the time from the date of the first dose of study treatment to the earliest date of assessment of disease progression or death by any cause in the absence of progression by RECIST v1.1. Disease Progression is defined using RECIST v1.1 as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Up to approximately 38 Months
Reported as:
Median · Months
Progression Free Survival (PFS) Per RECIST Version 1.1 by Investigator Assessment
MonthsCohort A (Dostarlimab + Bevacizumab + Niraparib)
Progression Free Survival (PFS) Per RECIST Version 1.1 by Investigator Assessment7.92 (4.17 to 10.87)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of the first dose of study treatment to the date of death due to any cause. Median and 95% CI are presented.

Time frame:
Up to approximately 38 Months
Reported as:
Median · Months
Overall Survival (OS)
MonthsCohort A (Dostarlimab + Bevacizumab + Niraparib)
Overall Survival (OS)22.05 (11.14 to 26.25)
SecondaryDuration of Response (DOR) Per RECIST Version 1.1 by Investigator Assessment

DOR was defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 based on Investigator's assessment or death by any cause. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm).

Time frame:
Up to approximately 38 Months
Reported as:
Median · Months
Duration of Response (DOR) Per RECIST Version 1.1 by Investigator Assessment
MonthsCohort A (Dostarlimab + Bevacizumab + Niraparib)
Duration of Response (DOR) Per RECIST Version 1.1 by Investigator Assessment11.76 (4.86 to 23.98)
SecondaryDisease Control Rate (DCR) Per RECIST Version 1.1 by Investigator Assessment

DCR was defined as the percentage of participants who have achieved best overall response of CR, PR, or stable disease (SD) per RECIST version 1.1 based on Investigator's assessment. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
Up to approximately 38 Months
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR) Per RECIST Version 1.1 by Investigator Assessment
Percentage of participantsCohort A (Dostarlimab + Bevacizumab + Niraparib)
Disease Control Rate (DCR) Per RECIST Version 1.1 by Investigator Assessment76.9 (66.0 to 85.6)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

Time frame:
Up to approximately 38 Months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsCohort A (Dostarlimab + Bevacizumab + Niraparib)
Number of Participants With Treatment-emergent Adverse Events (TEAEs)41
SecondaryNumber of Participants With Clinically Significant Changes in Clinical Laboratory Parameters - Chemistry, Coagulation, Hematology and Thyroid

Blood samples were collected for the analysis of clinical laboratory parameters - chemistry, coagulation, hematology and thyroid.

Time frame:
Up to approximately 38 Months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters - Chemistry, Coagulation, Hematology and Thyroid
ParticipantsCohort A (Dostarlimab + Bevacizumab + Niraparib)
Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters - Chemistry, Coagulation, Hematology and Thyroid0
SecondaryAbsolute Values in Urinalysis Parameter - Specific Gravity (Ratio)

Urine samples were collected at indicated time points for the assessment of specific gravity. Baseline is defined as the most recent non-missing measurement prior to or on the first administration of study drug.

Time frame:
Baseline (Day 1) and end of treatment (Up to approximately 32 months)
Reported as:
Mean · Ratio
Absolute Values in Urinalysis Parameter - Specific Gravity (Ratio)
RatioCohort A (Dostarlimab + Bevacizumab + Niraparib)
Baseline1.0149 ± 0.00794
End of treatment1.0162 ± 0.00786
SecondaryChange From Baseline in Cancer Antigen 125 (CA-125) at End of Treatment

Blood samples were collected for the analysis of CA-125. Baseline is defined as the most recent non-missing measurement prior to or on the first administration of study drug.

Time frame:
Baseline (Day 1) and end of treatment (Up to approximately 32 months)
Reported as:
Mean · Units per milliliter (U/mL)
Change From Baseline in Cancer Antigen 125 (CA-125) at End of Treatment
Units per milliliter (U/mL)Cohort A (Dostarlimab + Bevacizumab + Niraparib)
Change From Baseline in Cancer Antigen 125 (CA-125) at End of Treatment246.86 ± 608.985
SecondaryChange From Baseline in Vital Signs (Weight) at End of Treatment

Weight was measured in ordinary indoor clothing (without shoes) and was recorded at specified study visit. Baseline is defined as the most recent non-missing measurement prior to or on the first administration of study drug.

Time frame:
Baseline (Day 1) and end of treatment (Up to approximately 32 months)
Reported as:
Mean · kilogram
Change From Baseline in Vital Signs (Weight) at End of Treatment
kilogramCohort A (Dostarlimab + Bevacizumab + Niraparib)
Change From Baseline in Vital Signs (Weight) at End of Treatment-5.07 ± 5.475
SecondaryNumber of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status at Baseline and End of Treatment

Performance status assessments were based on 5-grade ECOG scale (from 0 to 4), where 0=fully active, able to carry on all pre-disease performance without restriction; 1=restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (e.g., light house work, office work); 2=ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours; 3=capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed or chair. Baseline is defined as the most recent non-missing measurement prior to or on the first administration of study drug.

Time frame:
Baseline (Day 1) and end of treatment (Up to approximately 32 months)
Reported as:
Count of participants · Participants
Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status at Baseline and End of Treatment
ParticipantsCohort A (Dostarlimab + Bevacizumab + Niraparib)
Baseline — Grade 018
Baseline — Grade 122
Baseline — Grade 20
Baseline — Grade 30
Baseline — Grade 40
End of Treatment — Grade 09
End of Treatment — Grade 120
End of Treatment — Grade 27
End of Treatment — Grade 31
End of Treatment — Grade 40

Adverse events

Collected over All-cause mortality, non-serious advents (Non-SAEs) and serious adverse events (SAE) were collected up to 38 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A (Dostarlimab + Bevacizumab + Niraparib)25/41 (61%)22/41 (53.7%)41/41 (100%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventCohort A (Dostarlimab + Bevacizumab + Niraparib)
Small intestinal obstructionGastrointestinal disorders4/41
Abdominal painGastrointestinal disorders3/41
VomitingGastrointestinal disorders2/41
AnaemiaBlood and lymphatic system disorders2/41
ThrombocytopeniaBlood and lymphatic system disorders2/41
HypertensionVascular disorders2/41
ColitisGastrointestinal disorders1/41
GastritisGastrointestinal disorders1/41
IleusGastrointestinal disorders1/41
Intestinal obstructionGastrointestinal disorders1/41
Most frequent other events
Showing 10 of 210
Most frequent other events
EventCohort A (Dostarlimab + Bevacizumab + Niraparib)
FatigueGeneral disorders30/41
NauseaGastrointestinal disorders28/41
VomitingGastrointestinal disorders23/41
HypertensionVascular disorders20/41
AnaemiaBlood and lymphatic system disorders19/41
Platelet count decreasedInvestigations17/41
Abdominal painGastrointestinal disorders16/41
HeadacheNervous system disorders16/41
ConstipationGastrointestinal disorders15/41
Aspartate aminotransferase increasedInvestigations15/41

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort A (Dostarlimab + Bevacizumab + Niraparib)
Mean63.8 ± 10.59
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A (Dostarlimab + Bevacizumab + Niraparib)
Female41
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort A (Dostarlimab + Bevacizumab + Niraparib)
Hispanic or Latino5
Not Hispanic or Latino36
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A (Dostarlimab + Bevacizumab + Niraparib)
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American2
White32
More than one race0
Unknown or Not Reported6
08

Study locations

10 sites
  • GSK Investigational Site
    Birmingham, Alabama 35249, United States
  • GSK Investigational Site
    Los Angeles, California 90095, United States
  • GSK Investigational Site
    Palo Alto, California 94304, United States
  • GSK Investigational Site
    Ventura, California 93003, United States
  • GSK Investigational Site
    Chicago, Illinois 60637, United States
  • GSK Investigational Site
    Boston, Massachusetts 02114, United States
  • GSK Investigational Site
    Boston, Massachusetts 02215, United States
  • GSK Investigational Site
    Rochester, Minnesota 55905, United States
  • GSK Investigational Site
    Durham, North Carolina 27710, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73104, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Apr 2022, 40 months.

Results were first posted in Apr 2023, 1 year after primary completion.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 40 months is close to that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2023
First posted
Mar 2, 2023
StartActual
Nov 15, 2018
Primary completionActual
Apr 1, 2022
CompletionActual
Apr 1, 2022
Results first posted
Apr 21, 2023
Last update
Apr 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05751629
Lead sponsor
Tesaro, Inc.
Responsible party
Sponsor
First posted
Mar 2, 2023
Start date
Nov 15, 2018
Primary completion
Apr 1, 2022
Completion
Apr 1, 2022
Results posted
Apr 21, 2023
Last update
Apr 21, 2023

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dostarlimab

Start the discussion